Development of bone marrow immunoscintigraphy using a Tc-99m labeled anti-NCA-95 monoclonal antibody
- 31 January 1995
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 22 (1) , 117-123
- https://doi.org/10.1016/0969-8051(94)e0069-u
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Expression of nonspecific cross-reacting antigen species in myeloid leukemic patients and healthy subjectsAnnals of Hematology, 1989
- RADIOIMMUNOIMAGING FOR DIAGNOSIS OF BONE MARROW INVOLVEMENT IN BREAST CANCER AND MALIGNANT LYMPHOMAThe Lancet, 1989
- Immunoscintigraphic localization of inflammatory lesions: Clinical experienceEuropean Journal of Nuclear Medicine and Molecular Imaging, 1988
- Monoclonal antibody against carcinoembryonic antigen (CEA) identifies two new forms of crossreacting antigens of molecular weight 90,000 and 160,000 in normal granulocytesMolecular Immunology, 1987
- Immunohistochemical localization and molecular characteristics of three monoclonal antibody‐defined epitopes detectable on carcinoembryonic antigen (CEA)International Journal of Cancer, 1985
- Non-specific cross-reacting antigen (NCA) in individual maturation stages of myelocytic cell seriesBritish Journal of Cancer, 1985
- Monoclonal antibodies identify a cea crossreacting antigen of 95 kD (NCA‐95) distinct in antigenicity and tissue distribution from the previously described NCA of 55 kDInternational Journal of Cancer, 1984